CHL1 and pancreatic ductal adenocarcinoma: Previous study reported that enhanced RBP TET1 expression could sensitize pancreatic ductal adenocarcinoma cells to 5FU and gemcitabine through inhibiting the CHL1-related Hedgehog signalling pathway [42].